Generated by AI
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.
Website360 Madison Avenue
New York, NY, 10017
United States
The latest articles about LUCD.
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of 0.00% and -24.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Investors talking about LUCD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.